PET clinics最新文献

Radiation-induced coronary artery disease (RI-CAD) is a significant cardiovascular complication for cancer survivors treated with thoracic radiation therapy (RT). Despite advances in RT techniques, exposure to the heart during treatment remains a critical factor influencing long-term cardiac outcomes, particularly in patients with breast and lung cancer. RI-CAD develops due to radiation-induced endothelial injury, inflammation, and accelerated atherosclerosis, presenting a unique and aggressive disease profile. This review explores the pathophysiology, risk factors, and diagnostic advancements for RI-CAD, emphasizing the role of PET in improving patient outcomes.

Positron Emission Tomography/Computed Tomography (PET/CT) plays a critical role in managing gastrointestinal (GI) cancers within radiation oncology. It enhances tumor detection, staging, and lymph node involvement assessment, leading to better-targeted radiation treatment. PET/CT also aids in delineating tumor volumes to minimize geographic misses, enabling precise dose escalation to metabolically active regions. Despite its benefits, PET/CT has limitations such as false positives and dependency on complementary imaging. Emerging technologies offer real-time adjustments and personalized treatments, advancing precision medicine in GI radiation oncology. Further research is needed to refine PET/CT integration for improved treatment outcomes and cost-effectiveness.

Prostate surface membrane antigen (PSMA)-PET imaging has significantly shaped the clinical management of prostate cancer, from localized to metastatic disease. It outperforms conventional imaging in both primary staging and detecting recurrence. PSMA-PET incorporation into the clinical workflow can alter treatment decisions, though the impact of observed stage migration on patient outcomes has yet to be well-characterized. There is growing interest in using PSMA-PET to predict treatment response across all stages of prostate cancer, and to select patients for PSMA radioligand therapy. Use of PSMA-PET will continue to expand for clinical applications as its role becomes better defined through prospective studies.

Radiation therapy for head and neck cancer is a cornerstone of treatment but can come with significant and lasting complications. Reduced vascularity and fibrosis heighten the risks of stroke, infection, and diminished quality of life. Advances in imaging technologies, such as fluorodeoxyglucose PET and sodium fluoride-PET, have emerged as critical tools for diagnosing and monitoring vascular inflammation and calcification, enabling earlier interventions and improved patient management. This review examines the pathophysiology of RT-induced damage, with a focus on vascular and connective tissue complications, and highlights the evolving role of PET imaging in early detection and management of these effects.

The investigation and application of PET modalities for the evaluation and treatment of patients with central nervous system (CNS) tumors continues to evolve, with anticipated increased uptake in the United States for both benign and malignant CNS tumors in the decade to come.

Radiation-induced injuries (RIIs) are significant complications of radiation therapy used in cancer treatments and affect organs in a systemic fashion such as the heart, lungs, liver, and bone marrow. Such ionizing radiation leads to inflammation, fibrosis, and/or irreparable DNA damage, each of which can significantly impact patient's quality of life, underscoring the need for advanced diagnostic and imaging techniques. A novel combination of PET/Computed Tomography (CT) with Quantitative MR Imaging has emerged as a crucial tool for early diagnosis and timely evaluation of RIIs. This review focuses on the important role of quantitative PET-CT-MR imaging in diagnosing and monitoring RIIs.

This review delves into the principles of PET imaging and radiomics, emphasizing their importance in detecting, staging, and monitoring various cancers. It highlights the clinical applications of PET radiomics in oncology, showcasing its impact on personalized cancer care. Additionally, the review addresses challenges such as standardizing PET radiomics, integrating multiomics data, and ethical concerns in clinical decision-making. Future directions are also discussed, including broader applications of PET radiomics in clinical trials, artificial intelligence integration for automated analysis, and incorporating multiomics data for a comprehensive understanding of tumor biology.

PET is a versatile imaging modality widely used in oncology for diagnosing, staging, predicting outcomes, and surveillance for a variety of cancers. In radiation oncology, combining PET and computed tomography imaging can markedly enhance treatment planning through improved target volume delineation. This review examines data and clinical approaches across 3 major cancer types to evaluate the role of PET in target volume delineation, with data and current approaches for thoracic, genitourinary, and head and neck malignancies detailed. Additionally, it emphasizes various practical applications of PET in radiation therapy planning, several of which have been recently demonstrated in clinical trials.